Ceregene, Inc. is a San Diego-based biotechnology company focused on the development and commercialization of gene therapies for the treatment of neurological disorders including Alzheimer’s disease, Parkinson’s disease, and amyotrophic lateral sclerosis (ALS).

Ceregene was acquired by Sangamo Biosciences, Inc.